Compound class:
Synthetic organic
Comment: HT1042 is reported to inhibit the β5i component of the 20S proteasome complex [1], which is constitutively expressed in dendritic cells and lymphocytes, and is induced in other cells by some cytokines to modulate antigen presentation [2]. Inhibitors selective for this immune system-associated 20S proteasome complex are expected to provide novel and more selective anti-inflammatory leads, compared to the current broad-spectrum proteasome inhibitor bortezomib used in the clinic.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Fan H, Angelo NG, Warren JD, Nathan CF, Lin G. (2014)
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. ACS Med Chem Lett, 5 (4): 405-10. [PMID:24900849] |
2. Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC, Welsh RM, Karow ML, Murphy AJ, Valenzuela DM et al.. (2012)
Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol, 13 (2): 129-35. [PMID:22197977] |